Washington, D.C., (October 29, 2020) – UsAgainstAlzheimer’s issued the following statement by George Vradenburg, chairman and co-founder, on the announcement today by C2N Diagnostics of a new, more widely accessible blood test. The blood test, which measures concentrations of amyloid beta and the presence of apolipoprotein E (ApoE) isoforms in blood, can be an important new tool for health care providers in evaluating patients for Alzheimer’s disease.

“This is an exciting and much-needed development. The advance of blood-based tests for use by physicians in the Alzheimer’s diagnostic process is occurring at a much more rapid pace than many in the field have appreciated.

“Accessible, affordable, and earlier testing by physicians is essential to understand the underlying cause of any cognitive impairment and to more effectively make or rule out a clinical Alzheimer’s diagnosis.

“It is equally important that government and private payers fairly reimburse for the costs of any Alzheimer’s test that can aid in a physician’s diagnosis of Alzheimer’s so that all Americans, regardless of income, can, if they wish, know whether they have Alzheimer’s or not.”

About UsAgainstAlzheimer’s

UsAgainstAlzheimer’s (UsA2) is a disruptive advocacy and research-focused organization that is pushing for expanding treatments and accelerating towards a cure for Alzheimer’s disease. UsA2’s transformative programming is laser-focused on proactive brain health across the lifespan and understanding what matters most across the lived experiences of those affected by Alzheimer’s in the service of preventing, treating and curing this disease. We are working to ensure that all communities have their voices heard and get a chance to be brain healthy from the earliest years while building resistance against possible cognitive decline.